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Abstract
Bioinformatic and direct cloning approaches have led to the identification of over 100 novel
miRNAs expressed in DNA viruses, although the function of the majority of these small
regulatory RNA molecules is unclear. Recently, a number of reports have now identified potential
targets of viral miRNAs, including cellular and viral genes as well as an ortholog of an important
immune-regulatory cellular miRNA. In this review, we will cover the identification and
characterization of miRNAs expressed in the herpesvirus family and discuss the potential
significance of their role in viral infection.
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Introduction
Herpesviruses belong to a large family of enveloped, double-stranded DNA viruses
disseminated throughout nature, which maintain persistent or latent infections during the
lifetime of the host [1]. Membership to the herpesviridae family is determined by virion
morphology, and gene expression involves a complex pattern of transcriptional regulation
during acute infection and during the establishment, maintenance and reactivation from
latency [1]. Herpesviruses are divided into three groups (alpha, beta and gamma) and
members of all three groups encode miRNAs, indicating that herpesviruses have utilized
RNAi throughout their evolution. Bioinformatic and direct cloning approaches have led to
the identification of over 100 novel miRNAs expressed in DNA viruses [2], although the
function of the majority of these small regulatory RNA molecules is unclear. Recently, a
number of reports have now identified the potential targets of viral miRNAs, including
cellular and viral genes as well as an ortholog of an important immune-regulatory cellular
miRNA [3–8]. In this review, we will cover the identification and characterization of
miRNAs expressed in the herpesvirus family and discuss the potential significance of their
role in viral infection.
Alpha-herpesviruses
Herpes simplex virus
Herpes simplex virus is a member of the alpha herpesvirus subfamily and is neurotropic in
nature, initially infecting the mucosal epithelia before establishing a latent infection in the
sensory neurons of the trigeminal ganglia. Reactivation of HSV-1 is associated with the
occurrence of the common cold sore around the mouth, but can cause more severe infections
in immunecompromised patients. Unlike HCMV, a number of animal models of infection
are available, as HSV-1 infects a range of different species. A number of well-established in
vitro models of latency also exist. Furthermore, HSV replicates rapidly in vitro, unlike EBV
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and KSHV, allowing for the analysis of the lytic stage of viral replication. These features
make HSV an attractive model for the study of viral miRNAs. Of particular interest is the
expression of a latency-specific, large non-coding RNA known as the latency-associated
transcript (LAT). Expressed exclusively within infected neurons, LATs are the only
transcript thought to be expressed by HSV-1 during latency [9]. Although no function has
been definitively shown for LAT, it has been suggested to be involved in the restriction of
viral trans-activating proteins and in blocking cellular apoptosis in response to infection,
both by unknown mechanisms [10, 11] (Fig. 1).
To date, two reports have described the identification of miRNAs expressed by HSV-1 close
to or within the LAT [4, 12]. The initial study using a bioinformatics approach predicted 13
pre-miRNAs located throughout the HSV-1genome [12]. Although northern blot analysis
identified three bands corresponding to the predicted pre-miRNAs, only one mature miRNA,
located upstream of the minor LAT transcript, was detected. Using a more directed approach
concentrating on the LAT region of the virus, another group characterized an additional
miRNA (miR-LAT) encoded within exon 1 of minor LAT. The authors demonstrated that
the expression of the LAT transcript alone could block apoptosis and that this activity was
dependent on the cellular RNAi pathway. Additional studies by this group suggested that
miR-LAT blocks apoptosis through targeting translation of the cellular genes, TGF-β1 and
SMAD3, through conserved sequences within the 3′UTRs [4].
Marek’s disease virus
Two cloning studies used a more comprehensive approach to identify miRNAs expressed by
chicken alpha herpesvirus Marek’s disease virus (MDV) 1 and 2 [13, 14]. In the first study,
eight miRNAs were identified in MDV-1 clustered within the LAT transcript and either side
of the viral oncogene, meq [13]. In MDV-2, 17 miRNAs were identified. Although there
was no sequence homology between the miRNAs of MDV-1 and 2, the miRNAs were
located in similar genomic regions of the viruses [14]. The miRNAs were detected in the
infected fibroblast cells as well as in the viral-induced tumor tissue from infected chickens.
As yet, there is no information on the potential function of these miRNAs, although
identification of multiple miRNAs encoded by MDV would suggest that additional miRNAs
are yet to be discovered in HSV.
Beta-herpesviruses
Human cytomegalovirus
A number of studies, including our own, have identified viral miRNAs encoded by the beta-
herpesvirus, human cytomegalovirus (HCMV) [15, 16]. HCMV infects a large percentage of
the population and, although generally benign, this virus is considered a significant pathogen
in immunosuppressed patients, either undergoing immunosuppressive therapy following
solid organ or bone marrow transplantation, or with AIDS [17–24]. In addition, HCMV is
one of the leading viral causes of birth defects [25]. Primary HCMV infection is followed by
a lifelong persistence of the virus in a latent state, although a low level of persistent infection
has not been ruled out as a relevant mechanism of viral maintenance.
A combination of both direct cloning and bioinformatics approaches were used to identify
miRNAs encoded by fibroblasts lytically infected with HCMV. A total of 11 HCMV-
encoded miRNAs have been identified to date and include miR-UL22A-1, miR-UL36-1,
miR-UL70-1, miR-UL112-1, miR-UL148D-1, miR-US4-1, miR-US5-1, miR-US5-2, miR-
US25-1, miR-US25-2, and miR-US33-1 (15,16, 26). Unlike the miRNAs encoded by the
alpha- and gamma-herpesviruses, which are found clustered within the regions of the
genome associated with the latent gene expression, the HCMV-encoded miRNAs are
located throughout the viral genome [16, 26]. Many are located in the intergenic regions,
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while miR-UL36-1 is found within the intronic region of UL36. Four of the identified
miRNAs(UL70-1, UL112-1, UL148D, and US33-1) are within the predicted coding regions
of HCMV and, as all four are directly antisense to the ORFs of the annotated genes, they are
predicted to cleave the expressed transcripts. However, studies performed in our lab have
shown that the UL114 transcript, which encodes the viral uracil DNA glycosylase is
resistant to miR-UL112-1-mediated cleavage, even though both RNAs are present during
acute infection(unpublished observation).
However, two recent studies have identified the potential target transcripts of miR-UL112-1.
Interestingly it appears that miR-UL112-1 is capable of targeting both cellular and viral
transcripts [7, 27].
In a study by our lab, a comparative bioinformatics approach was used to identify the
potential transcripts regulated by the HCMV-encoded miRNAs [27]. Of particular interest is
a cluster of targets identified for miR-UL112-1 within the major immediate early (MIE)
region of HCMV. These target sites were within the 3′UTR sequences of UL120, UL121
and UL123 (IE72). The MIE genes are known to express a number of regulatory proteins
that coordinate viral gene expression. Disruption of one of the miR-UL112-1 targets results
in a significant attenuation of viral replication following low multiplicity infections [28]. All
three target sites effectively down-regulated luciferase expression when cloned downstream
of the reporter gene in the presence of miR-UL112-1. In addition, expression of miR-
UL112-1 with a vector containing the major immediate early region significantly reduced
the levels of IE72 expression. Since IE72 is an important transactivator that is required for
efficient viral replication, we hypothesized that aberrant expression of miR-UL112-1 may
result in viral attenuation. HCMV DNA replication in cells transfected with synthetic miR-
UL112-1 RNA duplex was inhibited up to fivefold, indicating that expression of miR-
UL112-1 has the potential to attenuate the acute replication of HCMV. This may have
important implications for latency control of HCMV.
Recently, authors Stern-Ginossar et al. [7] demonstrated that miR-UL112-1 targets the major
histocompatibility complex class-I related chain B (MICB), a cellular gene involved in host
immune responses to viral infection. Using target prediction algorithms based on the
identification of repeated target sites within cellular 3′UTR sequences(RepTar; cRepTar), a
potential target site for miR-UL112-1 was identified within the 3′UTR of MICB. MICB is a
stress-induced ligand of NKG2D, a receptor present on NK cells. Activation of NK cells
through the association of MICB with NKG2D can lead to cell killing. Preventing this
interaction and the subsequent killing of infected cells would clearly benefit the virus.
Deletion of miR-UL112-1 led to an increase in MICB expression and susceptibility to NK
cell-mediated killing. Interestingly, HCMV also encodes the UL16 protein, which was
previously shown to inhibit MICB signaling by intracellular sequestration, suggesting a
level of redundancy in the targeting of MICB[15].
Murine cytomegalovirus
Murine cytomegalovirus (MCMV) belongs to the beta-herpesvirus family and has long
served as an important small animal model for HCMV infection and pathogenesis. Two
recent studies have identified multiple viral miRNAs encoded by MCMV [29, 30]. Using a
combination of bioinformatic and small RNA cloning approaches, authors Buck et al. and
Dolken et al. identified and characterized MCMV miRNAs expressed in the lytically
infected mouse fibroblasts. A total of 18 MCMV miRNAs were described, originating from
at least 12 pre-miRNAs. Similar to HCMV, the MCMV-encoded miRNAs are expressed
early during the lytic phase of replication and are found located throughout the viral genome
individually or in clusters. Nine of the miRNAs are located in predicted 3′UTRs, seven in
the coding sequences of predicted genes (m01, M55, M87, M88, m107 and m108) and two
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are located 5′ of the predicted ORFs (m01, −14nt and M95, > −1, 100nt). Two particular
clusters of miRNAs in proximity to m21, m22, M23, m107 and m108 include members that
are derived from complementary strands. None of the identified MCMV miRNAs show
significant homology to any of the HCMV-encoded miRNAs, with only the MCMV-
encoded miRNAs in the M23 region localized to a similar region as HCMV-miRNAs.
Northern blot analysis in combination with cycloheximide or foscarnet (PAA) treatment was
used to determine the expression kinetics during MCMV infection. While mature MCMV
miRNAs were detected as early as 4–8hpi, consistent with early kinetics, mature MCMV
miRNAs were not detected in cells treated with cyclohexamide, indicating that synthesis of
viral proteins may be required for their production. Interestingly, in a number of cases,
expression of MCMV pre-miRNA species were not blocked by cycloheximide, despite
efficient inhibition of the mature miRNAs that they encode. This pattern of expression is
similar to the HCMV miRNA miR-UL36-1: both the HCMV UL36 transcript and UL36 pre-
miRNA are expressed with immediate early kinetics, but the mature miR-UL36-1 is not
expressed on cycloheximide treatment [16]. However, prolonged cycloheximide treatment
may deplete cells of factors required to process pre-miRNAs into mature forms. Whether
production of mature miRNAs requires synthesis of viral proteins, or prolonged
cycloheximide treatment depletes factors necessary to process mature miRNAs, remains
unknown. mir-m108-1-3p, mir-m108-1-5p.2 and mir-m108-1 were sensitive to treatment
with PAA and, therefore, are considered late. There are no reported targets of MCMV-
encoded miRNAs. However, the use of MCMV as a model infection of β-herpesviruses will
enable crucial in vivo studies that are not possible with HCMV.
Gamma-herpesviruses
Epstein–Barr virus
Viral miRNAs were first shown to exist following the cloning of small RNAs from a B cell
line latently infected with Epstein–Barr virus (EBV) [31]. EBV was initially identified as the
etiological agent responsible for the lymphoproliferative disease, Burkitt’s lymphoma, and is
the prototypic member of the gamma herpesvirus subfamily. In addition to Burkitt’s
lymphoma, EBV is associated with a number of lymphoproliferative diseases in humans
including Castle-man’s disease, Hodgkin’s disease and primary effusion lymphoma (PEL).
Following the initial infection of the mucosal epithelia, EBV establishes a latent infection in
B lymphocytes and has a powerful transforming ability in these cells. EBV was found to
encode five miRNAs clustered within two genomic regions. miR-BHRF1-1, 2 and 3 are
located within the untranslated region (UTR) of BHRF1, an anti-apoptosis Bcl-2
homologue. miR-BHRF1-1 is located within the 5′UTR with miR-BHRF1–2 and 3 encoded
within the 3′UTR. miR-BART-1 and 2 are located within intronic regions of the BART
family of transcripts, which are extensively spliced. The BART family of transcripts has
been suggested to encode a number of proteins, although it remains to be convincingly
demonstrated that these proteins are expressed during viral infection [32]. Subsequent
investigation identified a further 22 EBV miRNAs not identified in the original study, due to
a large deletion in the B95-8 strain used for the initial cloning strategy [33, 34].
Three miRNAs encoded within the BART region, miR-BART16, miR-BART17-5p and
miR-BART1-5p, have since been shown to target sequences within the 3′UTR of the viral
latent membrane protein 1 (LMP1) following the transient transfection of an LMP1
expression plasmid and various BART-derived miRNAs [5]. LMP1 is an oncogenic protein
expressed in the majority of EBV-associated malignancies and is thought to induce
transformation through the activation of a number of cellular signaling pathways, including
NFκB, JNK, JAK/STAT, p38/MAP and Ras/MAPK [35]. The authors demonstrated a
correlative link between levels of BART miRNAs and LMP1, but have not, as yet,
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demonstrated a direct effect on LMP1 levels by BART miRNAs in infected cells. It is
currently unclear as to the functional relevance of LMP1 targeting by BART-derived
miRNAs, although overexpression of LMP1 can lead to the triggering of apoptosis. The
authors suggest that the regulation of LMP1 by BART miRNAs may dampen LMP1
expression levels to avoid triggering cell death. Indeed, expression of BART cluster 1
miRNAs reduced the sensitivity of LMP1-expressing cells to cisplatin-induced apoptosis. As
the majority of BART miRNAs have been deleted in the B95-8 strain, it would be of interest
to deter-mine whether cells infected with B95-8 produce higher levels of LMP1 than strains
with intact BART regions of the genome.
Kaposi’s sarcoma-associated herpesvirus
Cloning studies by multiple groups identified viral miRNAs encoded by a second human
gamma herpesvirus, Karposi’s sarcoma-associated herpesvirus (KSHV) [26, 36, 37]. Similar
to EBV, KSHV infection is associated with a number of tumors, most notably Kaposi’s
sarcoma, a skin malignancy common amongst AIDS patients and older men of
Mediterranean descent [38]. In common with all herpesviruses, KSHV has a complex viral
replication cycle involving initial acute replication followed by life-long latent infection
with the ability to reactivate [38]. In three independent studies, a total of 11 distinct miRNAs
were cloned from 2B-cell lines derived from the latently infected lymphomas. Of the 11
miRNAs, 10 are encoded within an approximately 4 kb region, previously thought to be
non-coding, between open reading frames (ORF) K12 (kaposin) and ORF71. A further
miRNA resides within the coding region of the Kaposin gene. Like EBV, KSHV latent
infection is characterized by limited gene expression. Many of the genes expressed during
latent infection flank the genomic region encoding the viral miRNAs. Detailed mapping of
the latent transcripts in two independent studies have subsequently identified three
overlapping transcripts driven by two separate promoters that have the potential to encode
10 of the 11 miRNAs within a single intron [39, 40]. All ten miRNAs were detected
following the transient transfection of the genomic region encoding the transcripts, strongly
suggesting that all ten miRNAs are in fact encoded for within the identified intron [40]. The
three spliced transcripts are also predicted to encode the kaposin ORF that contains the
additional miRNA. As the transcript would be cleaved to release the pre-miRNA stem loop,
processing of this miRNA by Drosha would theoretically preclude the expression of
Kaposin protein, leading to a novel form of gene regulation. However, as both miRNA and
Kaposin protein are detected during latent infection, sufficient Kaposin transcript apparently
escapes Drosha processing to allow translation of the Kaposin mRNA. Regardless of the
precise mechanism, the close association of the viral miRNAs with the expression of
Kaposin does suggest the possibility of a functional association. The Kaposin gene encodes
for a number of different proteins, including Kaposin B, which was shown to bind and
activate MAPK-associated protein kinase 2 (MK2) [41]. Activation of MK2 by Kaposin B
leads to an increase in cytokine expression in KSHV-infected cells by blocking the
destabilizing effect of AU-rich elements (ARE’s) within the 3′UTRs of cytokine mRNAs.
Whether the miRNAs possess any functional relevance to this mechanism, or to one of the
Kaposin gene products, awaits further investigation. Ten miRNAs have also been identified
in the related Rhesus monkey rhadinovirus (RRV) using a cloning approach [42]. Although
the miRNAs expressed by RRV show no sequence homology to those encoded by KSHV,
they are encoded within the same genomic region as the miRNAs of KSHV.
Two recent reports from Rolf Renne’s group have suggested cellular targets for miRNAs
expressed by KSHV [6,8]. In the first study, Samols et al. [8] constructed stable cell lines
expressing ten KSHV miRNAs derived from the single intronic transcript described above.
To identify the potential cellular targets of the KSHV miRNAs, global transcript levels were
determined by microarray analysis and compared to negative control cell lines. Previous
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studies have shown that transcript degradation can occur from miRNA targeting, even when
the target sequence is not fully complementary. Therefore, microarray analysis has proven to
be an effective tool for identifying potential target transcripts of miRNAs. In this study, the
authors found 65 genes downregulated in the miRNA-expressing cells, including genes
involved in proliferation, immune modulation, angiogenesis and apoptosis. More detailed
analysis demonstrated that one of the identified genes, thrombospondin-1 (THBS-1), was
targeted by all ten of the KSHV miRNAs examined through multiple binding sites within
the 3′UTR. Surprisingly, despite the high level of redundancy in targeting, inhibition of any
one of the KSHV miRNAs led to derepression of the target transcript. THBS-1 has anti-
proliferative and anti-angiogenic properties and would therefore represent an attractive
target for a prooncogenic virus such as KSHV.
In a second study, Skalsky et al. [6], discovered that the seed sequence of miRK12-11 of
KSHV exactly matched that of the cellular miRNA miR-155. This was of particular interest
as overexpression of miR-155 has been associated with a number of B cell lymphomas and
solid organ tumors, as well as the development of B cell lymphomas intransgenic miR-155
overexpressing mice [43, 44]. It is currently unclear as to the role of miR-155 in the
development of tumors, but expression of miR-155 has been shown to drive B cell germinal
center development and is required for normal B and T cell activation and maturation.
Skalsky et al. suggest that miR-K12-11 may mimic the regulatory functions of miR-155 to
the advantage of the virus, possibly by inducing survival and proliferation of the infected
cells. Although microarray data demonstrate similar regulation of transcripts by miR-155
and miR-K12-11, functional data showing rescue of miR-155 deletion phenotypes by miR-
K12-11 would be particularly compelling. The use of cellular miRNA orthologs by viruses
is an attractive concept, as the virus would be able to highjack the target sequences already
evolved by the host, thereby avoiding potential problems caused by sequence
polymorphisms that could lead to the disruption of viral targeting of the cellular transcript. It
is therefore somewhat surprising that more viral miRNAs do not show sequence similarities
with known cellular miRNAs. One possible explanation is that more cellular orthologs of
viral miRNAs do exist, but have not yet been discovered. As additional cellular and viral
miRNAs are identified, further examples of virally expressed orthologs of cellular miRNAs
may be revealed.
Murine herpesvirus-68
A third member of the gamma herpesviruses, and a distant relative of EBV and KSHV, has
been shown to express miRNAs during latent infection [26]. Murine herpesvirus-68
(MHV-68) infects and establishes a latent infection within B cells of the germinal centers of
the spleen. Following cDNA cloning of small RNAs from a stably infected B cell line, nine
miRNAs were identified, again clustered within a genomic region of the virus known to
encode latency-associated transcripts. Of particular interest is the existence of eight virally
encoded tRNA-like transcripts (vtRNA), co-linear with the identified miRNAs. Northern
blot analysis and secondary RNA structure predictions suggest that these miRNAs are
encoded within two terminal stem loops downstream of each vtRNA transcript. These
sequences are also predicted to encode a further six potential miRNAs. However, these
miRNAs have so far not been detected. Each of the vtRNAs is driven by an RNA
polymerase III promoter, and would therefore be predicted to drive expression of the
associated miRNAs. This situation is unique to viruses, with all other cellular miRNA
transcripts identified being driven by RNA polymerase II transcription. In vivo analysis of
mouse tissues following MHV-68 infection has identified the expression of vtRNAs during
both lytic and latent infections [45].Although no function has been identified for either the
MHV-68 miRNAs or the vtRNAs, vtRNAs 1–4 (and their associated miRNAs) can be
deleted from the virus with no obvious effect on the ability of the virus to establish or
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reactivate from latency, suggesting either a subtle role for these miRNAs or a certain level
of redundancy in their actions [46].
Conclusion
From the recent studies discussed above, it is likely that herpesviruses make use of miRNAs
for a variety of aspects including inhibiting apoptosis, immune avoidance, cellular
proliferation and control of viral gene expression and replication. Targets of herpesvirus
miRNAs include both cellular and viral transcripts. Interestingly, miRUL112-1 of HCMV
has been shown to regulate both multiple viral genes as well as a cellular gene [7, 27]. In
addition to the identification of target genes, a viral ortholog of an important cellular
miRNA has also been discovered in KSHV that may prove to contribute to the oncogenic
nature of the virus [6]. It is perhaps unsurprising that herpesviruses make extensive use of
small RNA regulators of gene expression. The long-term nature of herpesvirus infections
requires strict regulation of viral genes and multiple strategies to avoid both the innate and
adaptive host defense mechanisms. miRNAs have the ability to regulate multiple genes,
while their small size and RNA nature avoids triggering potentially detrimental host defense
responses. They are also economic in terms of genomic space, as they require little coding
sequence, an aspect attractive for even large viruses whose genome size is restrictive.
Although a number of studies have now been published on targets and possible functions for
viral miRNAs, a great deal more work will be required to truly understand the functional
role of viral miRNAs. One of the major challenges ahead will be to convincingly show a
phenotypic effect of viral miRNAs in the context of a physiologically relevant infection.
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Fig. 1.
Proposed functions of herpesvirus miRNAs. Recent reports have identified a number of
potential targets for viral miRNAs. In HSV-1,miR-LAT was reported to block apoptosis by
targeting the cellular transcripts encoding TGFβ and SMAD3 [4]. HCMV miR-UL112-1 has
been reported to target both the viral transactivator IE72 and the cellular immune ligand
MICB [3,7]. In KSHV multiple miRNAs were found to target THBS-1. miR-K12-11 of
KSHV was also identified as an ortholog of the important immunoregulatory miRNA
miR-155 [6,8]. In EBV, miRNAs from the BART region were found to efficiently target
expression of the oncogenic latency gene LMP1 [5]
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